Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on cli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Wawruszak, Anna, Kalafut, Joanna, Okon, Estera, Czapinski, Jakub, Halasa, Marta, Przybyszewska, Alicja, Miziak, Paulina, Okla, Karolina, Rivero-Muller, Adolfo, Stepulak, Andrzej
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406474/
https://ncbi.nlm.nih.gov/pubmed/30691229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020148
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars